Previous 10 | Next 10 |
Gainers: Milestone Pharmaceuticals (NASDAQ: MIST ) +105% . More news on: Milestone Pharmaceuticals Inc., RigNet, Inc., Brightcove Inc., Stocks on the move, , Read more ...
Mexco Energy (NYSEMKT: MXC ) -9% . More news on: Mexco Energy Corporation, Northern Dynasty Minerals Ltd., Limelight Networks, Inc., Stocks on the move, , Read more ...
Aurinia Pharmaceuticals (NASDAQ: AUPH ) has priced its public offering of ~13.3M common shares at $15.00/share, for gross proceeds of ~$200M. More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, , Read more ...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the pricing of its underwritten public offering of 13,333,33...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the U.S. Food and Drug Administration (FDA) accepted the filing of a New Drug Application (NDA) for Voclosporin. Voclosporin is a potential treatment fo...
Mexco Energy (NYSEMKT: MXC ) +153% . More news on: Mexco Energy Corporation, Oblong Inc., Oragenics, Inc., Stocks on the move, , Read more ...
The FDA has accepted Aurinia Pharmaceuticals' (NASDAQ: AUPH ) New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis, an inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus. More news on: Aurinia Pharmaceuticals In...
- FDA grants Priority Review and sets PDUFA date of January 22, 2021 - Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indicat...
- Voclosporin ophthalmic solution (VOS) results anticipated in the fourth quarter of 2020 – Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclos...
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that additional safety data from the completed AURORA pivotal ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...